CytoMed Therapeutics (GDTC) Retained Earnings (2021 - 2025)

CytoMed Therapeutics has reported Retained Earnings for 5 years, with the latest figure at $60393.7 in Q4 2025.

• Quarterly Retained Earnings rose 249.44% year-over-year to $60393.7 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $60393.7 (up 249.44% YoY) and the FY2025 annual result came in at -$14.6 million, down 36284.82% from the prior year.
• Retained Earnings grew to $60393.7 in Q4 2025 per GDTC's latest filing, from -$17.1 million in the prior quarter.
• Over five years, Retained Earnings peaked at $60393.7 in Q4 2025 and troughed at -$17.1 million in Q2 2025.
• A 5-year average of -$5.9 million and a median of -$3.0 million in 2022 frame the typical range for Retained Earnings.
• The sharpest annual moves came in 2022 and 2025: Retained Earnings slumped 25777.63% in 2022, then soared 249.44% in 2025.
• Over 5 years, Retained Earnings stood at -$22828.8 in 2021, then slumped by 25777.63% to -$5.9 million in 2022, then jumped by 97.27% to -$161028.0 in 2023, then soared by 74.9% to -$40413.2 in 2024, then surged by 249.44% to $60393.7 in 2025.
• According to Business Quant data, Retained Earnings over the past three periods registered $60393.7, -$17.1 million, and -$40413.2 for Q4 2025, Q2 2025, and Q4 2024 respectively.